Check out market updates

Edgewise reports positive interim results from Becker muscular dystrophy treatment trial

BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX), a clinical-stage biopharmaceutical company developing drugs to treat muscular dystrophy, has observed positive two-month interim results from its ongoing study of EDG-5506, a … Continued
Source: BizWest

Leave a Reply

Your email address will not be published. Required fields are marked *